UBA52 Antibody

What is UBA52 and why is it important in cellular research?

UBA52 (Ubiquitin A-52 residue ribosomal protein fusion product 1) is a ubiquitin hybrid gene that encodes a fusion protein consisting of ubiquitin at the N-terminus and ribosomal protein L40 at the C-terminus . This fusion protein plays critical roles in multiple cellular processes, making it an important research target. The ubiquitin component participates in post-translational modifications through ubiquitination, while the ribosomal protein component contributes to protein synthesis .

The significance of UBA52 in research stems from its involvement in multiple pathological conditions. It has been implicated in neurodegenerative disorders, particularly Parkinson's disease, where it interacts with α-synuclein, HSP90, and E3-ubiquitin ligase CHIP . It also plays roles in cancer development, particularly hepatocellular carcinoma, where it affects cell proliferation and migration through autophagy regulation via EMC6 . Additionally, UBA52 has been identified as a potential biomarker for diabetic kidney disease and has been detected at elevated levels in the urine of patients with this condition .

What are the typical applications for UBA52 antibodies in research?

UBA52 antibodies serve multiple research applications across various experimental platforms. The primary application is Western blotting, where anti-UBA52 antibodies can detect the protein at approximately 11 kDa in cell lysates, such as in Raji cells . Western blotting with these antibodies allows researchers to quantify UBA52 expression levels and assess changes under various experimental conditions or disease states.

Beyond Western blotting, these antibodies are valuable for immunoprecipitation experiments to study protein-protein interactions. For instance, co-immunoprecipitation studies have demonstrated UBA52's interaction with α-synuclein, HSP90, and E3-ubiquitin ligase CHIP . Immunohistochemistry and immunofluorescence applications enable localization studies of UBA52 within cells and tissues, revealing its distribution patterns. For example, microscopic analysis using FLAG-UBA52-GFP vectors has shown that while FLAG-GFP expresses in both cytosol and nucleolus, RPL40-GFP (the C-terminal component of UBA52) is not expressed in the nucleolus .

ELISA-based detection methods using UBA52 antibodies have also been employed, particularly for biomarker studies, such as measuring UBA52 levels in urine samples from patients with diabetic kidney disease .

How can I confirm the specificity of a UBA52 antibody?

Confirming antibody specificity is crucial for reliable research outcomes. For UBA52 antibodies, several validation approaches should be employed:

• Positive and negative control samples: Using cell lines or tissues known to express UBA52 (positive controls) alongside those with low or no expression (negative controls). For instance, Raji cell lysates have been validated for UBA52 detection .

• Knockdown/knockout validation: Implementing siRNA or shRNA to reduce UBA52 expression and confirm corresponding reduction in antibody signal. Several studies have successfully used this approach to validate UBA52 antibody specificity .

• Overexpression validation: Transfecting cells with UBA52 expression vectors to confirm increased antibody signal. FLAG-UBA52-GFP and other tagged constructs have been used for this purpose .

• Western blot analysis: Verification that the antibody detects a band of the expected molecular weight (approximately 11 kDa for UBA52) . Additionally, assess for non-specific bands that might indicate cross-reactivity with other proteins.

• Peptide competition assay: Pre-incubating the antibody with the immunizing peptide should block specific binding and eliminate the signal if the antibody is truly specific to UBA52.

It's worth noting that UBA52 is cleaved into ubiquitin and ribosomal protein L40 components, so antibodies targeting different regions may detect different forms or fragments of the protein .

How should I design experiments to study UBA52's role in protein ubiquitination?

Designing experiments to investigate UBA52's role in protein ubiquitination requires a multifaceted approach that captures both its function as a ubiquitin supplier and its specific regulatory activities. Consider the following methodological framework:

• Expression modulation strategies: Implement both loss-of-function and gain-of-function approaches. For knockdown experiments, siRNA targeting UBA52 has been successfully used in multiple cell lines . For overexpression studies, several vectors have been employed including FLAG-UBA52-GFP and other tagged constructs.

• Cleavage-resistant mutants: To distinguish between effects of the ubiquitin moiety versus the complete fusion protein, utilize cleavage-resistant UBA52 mutants. These can be generated by mutating the terminal region of ubiquitin (G75/76A), which prevents the separation of ubiquitin from RPL40 . FLAG-UBA52-GFP (CR) expression vectors can be employed for this purpose.

• Site-specific ubiquitination analysis: For studying the specific role of UBA52 in K48 or K63 ubiquitination, utilize UBA52 mutants like K48R and K63R. These mutations affect specific lysine residues involved in different types of polyubiquitin chain formation .

• In vitro ubiquitination assays: These are critical for determining the direct role of UBA52 in protein ubiquitination. Such assays have revealed, for example, that the lysine-63 residue of UBA52 is essential for CHIP-mediated HSP90 ubiquitylation .

• Proteasome activity measurements: Since ubiquitination often targets proteins for proteasomal degradation, measuring proteasome activity in the presence of modulated UBA52 provides insight into its functional impact .

This experimental design allows for comprehensive analysis of both general and specific functions of UBA52 in ubiquitination pathways, distinguishing its role from other ubiquitin-coding genes like UBC .

What are the key considerations for using UBA52 antibodies in co-immunoprecipitation experiments?

Successful co-immunoprecipitation (co-IP) experiments with UBA52 antibodies require careful attention to several technical aspects:

• Antibody selection: Choose antibodies that recognize epitopes not involved in protein-protein interactions to avoid interference with binding partners. Antibodies targeting the C-terminus of UBA52 may be preferable for certain applications .

• Crosslinking considerations: Given UBA52's role in transient protein interactions during ubiquitination processes, consider using reversible crosslinking agents like DSP (dithiobis[succinimidyl propionate]) to stabilize protein complexes before immunoprecipitation.

• Buffer optimization: Use buffers that preserve protein-protein interactions while maintaining adequate stringency. For UBA52 co-IP experiments, researchers have successfully used buffers containing HEPES (200 nM, pH 7.4), sucrose (250 mM), KCl (10 mM), MgCl2 (1.5 mM), EGTA (1 mM), EDTA (1 mM), DTT (1 mM), PMSF (1 mM), nonidet P40 (0.05%), and protease inhibitor cocktail .

• Control experiments: Include appropriate controls such as:

  • IgG isotype control to identify non-specific binding

  • Input samples to confirm the presence of potential interacting proteins

  • Reverse co-IP (using antibodies against suspected interacting partners)

• Expression system considerations: For studying specific interactions, co-transfection of tagged constructs can be valuable. For example, 293T cells have been effectively transfected with recombinant plasmids expressing Flag-UBA52 and HA-EMC6 using Lipofectamine 2000 reagent for co-IP experiments .

These methodological considerations can help ensure robust and reproducible results when investigating UBA52's interactions with proteins such as α-synuclein, HSP90, E3-ubiquitin ligase CHIP , or EMC6 .

How do I interpret changes in UBA52 expression levels in disease models?

Interpreting changes in UBA52 expression in disease models requires careful consideration of its dual role as both a ubiquitin supplier and a ribosomal protein, along with contextual analysis of the specific disease mechanism. Consider this interpretive framework:

• Baseline determination: Establish normal UBA52 expression levels in your model system using appropriate controls. Note that baseline expression may vary across tissue types and cell lines.

• Contextual analysis based on disease type:

  • In neurodegenerative disorders like Parkinson's disease, decreased UBA52 abundance has been associated with downregulation of tyrosine hydroxylase and neuronal death . This suggests a potential neuroprotective role.

  • In diabetic kidney disease, increased urinary UBA52 levels correlate with disease progression, suggesting its potential as a biomarker .

  • In hepatocellular carcinoma (HCC), elevated UBA52 expression is associated with poor prognosis, and it promotes tumor growth and metastasis by regulating autophagy through EMC6 .

• Multi-parameter correlation analysis: Correlate UBA52 expression with other relevant markers. For example:

  • In Parkinson's disease models, correlate with α-synuclein levels and tyrosine hydroxylase expression

  • In diabetic kidney disease, correlate with serum creatinine (r=0.468), GFR (r=-0.300), and proteinuria levels (r=0.484)

• Temporal dynamics: Consider the timing of expression changes relative to disease progression. Early changes may indicate involvement in disease initiation, while later changes might reflect compensatory mechanisms.

• Differential impact of expression changes:

  • Moderate reduction may primarily affect ribosomal function and protein synthesis

  • More substantial changes may impact both ubiquitination processes and ribosomal functions

By systematically analyzing these parameters, researchers can better interpret whether UBA52 expression changes represent causal factors, compensatory responses, or biomarkers of disease progression.

How can I distinguish between UBA52's roles in ubiquitination versus ribosomal function?

Dissecting the dual roles of UBA52 in ubiquitination and ribosomal function requires sophisticated experimental approaches that can selectively target each function. Consider the following methodological strategies:

• Domain-specific mutants: Utilize constructs with mutations that selectively impair either the ubiquitin or the RPL40 domain:

  • For ubiquitin functionality: Use lysine-to-arginine mutations (K48R, K63R) that affect specific ubiquitination pathways without altering the protein's structure

  • For ribosomal functionality: Target conserved residues in the RPL40 domain that are crucial for ribosome incorporation

• Cleavage-dependent analysis: Compare the effects of wild-type UBA52 versus cleavage-resistant UBA52 (G75/76A mutations) . This approach can reveal which functions depend on the release of free ubiquitin versus the intact fusion protein.

• Selective rescue experiments: In UBA52-knockdown cells, perform rescue experiments with:

  • Wild-type UBA52

  • Free ubiquitin expression construct

  • RPL40 expression construct

  • Cleavage-resistant UBA52

• Differential impact assessment:

  • For ubiquitination function: Monitor global ubiquitination patterns, specific substrate ubiquitination (e.g., HSP90 ), and proteasome activity

  • For ribosomal function: Assess protein synthesis rates using techniques like O-propargyl-puromycin (OPP) incorporation , polysome profiling, and ribosome assembly analysis

• Subcellular localization studies: Analyze the differential localization of UBA52 components. For example, microscopic analysis has revealed that while FLAG-GFP expresses in both cytosol and nucleolus, RPL40-GFP is not expressed in the nucleolus .

This comprehensive approach allows researchers to attribute specific cellular phenotypes to either the ubiquitination or ribosomal functions of UBA52, providing deeper insight into its multifaceted roles in cellular processes.

What are the best approaches for studying UBA52's role in autophagy regulation?

Recent research has revealed UBA52's involvement in autophagy regulation, particularly in the context of hepatocellular carcinoma . To effectively study this role, consider these methodological approaches:

• Autophagy marker analysis: Monitor canonical autophagy markers following UBA52 modulation:

  • LC3-I to LC3-II conversion via Western blotting

  • p62/SQSTM1 degradation

  • Formation of GFP-LC3 puncta using fluorescence microscopy

  • Autophagic flux using tandem fluorescent-tagged LC3 (tfLC3) or bafilomycin A1 treatment

• Mechanistic pathway dissection: Since UBA52 has been shown to regulate autophagy via EMC6 in HCC cells , investigate the molecular interactions between UBA52 and autophagy regulators:

  • Co-immunoprecipitation to confirm physical interactions

  • Proximity ligation assays to visualize protein interactions in situ

  • Expression correlation studies between UBA52 and autophagy-related genes

• Genetic modulation strategies:

  • Use lentiviral vectors carrying shRNA targeting UBA52 for stable knockdown

  • Employ lentiviral UBA52 overexpression vectors

  • Use CRISPR/Cas9 for complete knockout

  • Create conditional expression systems for temporal control

• Selective autophagy investigation: Determine if UBA52 affects general autophagy or specific selective autophagy pathways:

  • Mitophagy (selective autophagy of mitochondria)

  • ER-phagy (endoplasmic reticulum autophagy)

  • Aggrephagy (clearance of protein aggregates)

• In vivo validation: Establish animal models with modulated UBA52 expression to assess autophagy in physiological contexts:

  • Subcutaneous and metastatic tumor models in nude mice have been successfully used to evaluate the effects of UBA52 on HCC cell proliferation and migration in vivo

These approaches provide a comprehensive framework for investigating UBA52's role in autophagy regulation, potentially revealing new therapeutic targets for diseases where autophagy dysregulation contributes to pathology.

How can I investigate UBA52's potential as a biomarker in clinical samples?

UBA52 shows promise as a biomarker for several conditions, particularly diabetic kidney disease . To rigorously investigate its biomarker potential, implement this methodological framework:

• Sample collection and processing optimization:

  • For urine samples: Standardize collection timing (first morning vs. random), processing protocols, and storage conditions

  • For tissue samples: Optimize fixation and preservation methods to maintain UBA52 integrity

  • For blood/serum samples: Develop standardized separation and storage protocols

• Detection method validation:

  • ELISA: Two-step ELISA has been successfully employed to quantify UBA52 in urine samples from diabetic patients

  • Western blotting: Validate antibody specificity and establish quantification protocols

  • Mass spectrometry: For unbiased detection and absolute quantification

• Clinical correlation analyses:

  • Conduct Spearman's correlation analysis to assess relationships between UBA52 levels and clinical parameters

  • Perform multiple linear regression to identify independently associated factors

  • For diabetic kidney disease, significant correlations have been found between urinary UBA52 levels and serum creatinine (r=0.468, p<0.001), GFR (r=-0.300, p=0.004), and proteinuria (r=0.484, p<0.001)

• Diagnostic performance evaluation:

  • Construct Receiver Operating Characteristic (ROC) curves to assess sensitivity and specificity

  • Calculate Area Under the Curve (AUC) values for different clinical contexts

  • In diabetic kidney disease studies, the AUC of urinary UBA52 in diagnosing T2DM and DKD was 0.751 and 0.755, respectively

• Comparative biomarker assessment:

  • Compare UBA52's performance against established biomarkers for the condition under study

  • Evaluate whether UBA52 provides additive diagnostic value when combined with existing markers

Table 1: Correlation of urinary UBA52 levels with clinical parameters in diabetic kidney disease patients

This structured approach provides a robust framework for evaluating UBA52's potential as a clinical biomarker across various disease contexts.

What are common technical challenges when working with UBA52 antibodies?

Researchers frequently encounter several technical challenges when working with UBA52 antibodies that can affect experimental outcomes. These issues and their solutions include:

• Protein cleavage detection issues:

  • Challenge: UBA52 is naturally cleaved into ubiquitin and ribosomal protein L40 components, making it difficult to determine which form is being detected.

  • Solution: Use antibodies targeting specific regions (N-terminal vs. C-terminal) and compare with cleavage-resistant UBA52 mutants (G75/76A) . For comprehensive analysis, use multiple antibodies targeting different epitopes.

• Cross-reactivity concerns:

  • Challenge: Antibodies may cross-react with free ubiquitin or other ubiquitin fusion proteins.

  • Solution: Validate specificity using UBA52 knockout/knockdown samples as negative controls . Additionally, perform peptide competition assays with the immunizing peptide to confirm specificity.

• Epitope masking during protein interactions:

  • Challenge: UBA52's interactions with proteins like HSP90 and E3-ubiquitin ligase CHIP may mask epitopes.

  • Solution: Try multiple antibodies targeting different regions or use denaturing conditions for detection of total UBA52, recognizing that this may disrupt native interactions.

• Detection sensitivity limitations:

  • Challenge: Low abundance of UBA52 in certain samples may limit detection.

  • Solution: Implement signal amplification techniques or consider immunoprecipitation before Western blotting to concentrate the target protein.

• Subcellular localization discrepancies:

  • Challenge: Different localization patterns between the ubiquitin and RPL40 components can complicate interpretation .

  • Solution: Use domain-specific antibodies or fluorescently tagged constructs with appropriate controls to accurately determine localization patterns of specific components.

Addressing these technical challenges through proper controls and method optimization is essential for generating reliable data when studying UBA52.

How can I resolve data inconsistencies in UBA52 expression analysis across different experimental platforms?

Data inconsistencies across different platforms when analyzing UBA52 expression are common and can arise from various sources. Here's a systematic approach to resolve such discrepancies:

• Platform-specific normalization strategies:

  • RNA-seq vs. qRT-PCR: For RNA-seq, use TPM (Transcripts Per Million) or FPKM (Fragments Per Kilobase Million) normalization; for qRT-PCR, use multiple reference genes validated for your specific tissue/cell type

  • Western blot vs. mass spectrometry: For Western blotting, normalize to total protein (using stain-free technology) rather than single housekeeping proteins; for mass spectrometry, use label-free quantification with appropriate normalization algorithms

• Isoform-specific expression analysis:

  • Challenge: Different detection methods may preferentially detect specific isoforms or processed forms of UBA52.

  • Solution: Design primers or antibodies that can distinguish between the full-length fusion protein and its cleaved components. For Western blotting, use antibodies that specifically detect either the ubiquitin portion or the RPL40 portion .

• Cross-validation approach:

  • Implement at least three independent methods to quantify UBA52:

    • mRNA expression (qRT-PCR or RNA-seq)

    • Protein expression (Western blotting)

    • Functional readouts (e.g., protein synthesis assay with OPP)

• Time-course analysis:

  • Discrepancies may reflect different temporal dynamics of mRNA versus protein expression.

  • Perform time-course experiments following stimulation or treatment to capture these differences.

• Experimental condition standardization:

  • Standardize cell culture conditions, sample preparation, and analysis protocols across platforms.

  • Document all experimental variables that could affect UBA52 expression or detection.

By systematically addressing these factors, researchers can better understand the source of inconsistencies and develop a more accurate integrated view of UBA52 expression patterns.

What controls should be included when studying UBA52's role in disease models?

Proper experimental controls are critical for accurately interpreting UBA52's role in disease models. Implement this comprehensive control strategy:

• Genetic manipulation controls:

  • Knockdown/knockout controls:

    • Non-targeting siRNA/shRNA controls for RNAi approaches

    • Empty vector controls for CRISPR/Cas9 knockouts

    • Rescue experiments with wild-type UBA52 to confirm specificity of observed phenotypes

  • Overexpression controls:

    • Empty vector controls (e.g., pcDNA3.1 has been used to adjust DNA amounts in transfections)

    • Overexpression of mutant UBA52 variants (e.g., cleavage-resistant UBA52, K48R or K63R mutants)

    • Expression level verification to account for dose-dependent effects

• Disease model validation controls:

  • Positive controls: Samples with confirmed disease phenotypes (e.g., A53T transgenic mice for Parkinson's disease models)

  • Negative controls: Age-matched wild-type samples

  • Disease progression markers: Monitor established biomarkers alongside UBA52 (e.g., tyrosine hydroxylase for Parkinson's disease , proteinuria for diabetic kidney disease )

• Functional outcome controls:

  • Pathway inhibition controls: Use specific inhibitors of relevant pathways (e.g., proteasome inhibitors for ubiquitination studies, autophagy inhibitors like bafilomycin A1 for autophagy studies)

  • Positive functional controls: For protein synthesis assays, include cycloheximide treatment as a complete inhibition control

  • Technical readout controls: Include standards for quantitative measurements

• Species and model comparison controls:

  • Test hypotheses across multiple cell lines (e.g., both DLD-1 and HeLa cells have been used to confirm UBA52's role in protein synthesis)

  • Compare findings between in vitro and in vivo models where possible

  • Consider species differences in UBA52 function and regulation

This comprehensive control strategy helps distinguish UBA52-specific effects from experimental artifacts and establishes causality in disease models.

What are emerging techniques for studying UBA52 function in single cells?

Emerging single-cell techniques offer exciting opportunities to investigate UBA52 function with unprecedented resolution, revealing cell-to-cell variability and temporal dynamics:

• Single-cell RNA sequencing (scRNA-seq) applications:

  • Profiling UBA52 expression heterogeneity within tissues

  • Correlating UBA52 expression with cell states or disease progression

  • Identifying cell populations where UBA52 plays critical roles

  • Computational strategies: Pseudotime analysis to track UBA52 expression changes during cellular transitions

• Single-cell proteomics approaches:

  • Mass cytometry (CyTOF) with UBA52 antibodies to quantify protein levels across thousands of cells

  • Single-cell Western blotting to detect UBA52 protein forms in individual cells

  • Microfluidic-based proteomics platforms for analyzing UBA52 and its interacting partners

• Live-cell imaging innovations:

  • CRISPR-based tagging of endogenous UBA52 with fluorescent proteins

  • Optogenetic control of UBA52 expression or cleavage

  • Fluorescence resonance energy transfer (FRET) sensors to monitor UBA52 interactions or cleavage in real-time

  • Single-molecule tracking to visualize UBA52 dynamics within living cells

• Spatial transcriptomics and proteomics:

  • Multiplexed RNA fluorescence in situ hybridization (FISH) to localize UBA52 mRNA

  • Imaging mass cytometry to map UBA52 distribution within tissue contexts

  • Spatial proteomics to resolve UBA52 localization within subcellular compartments

• Functional genomics at single-cell resolution:

  • Single-cell CRISPR screens targeting UBA52 and related pathway components

  • Perturb-seq approaches combining genetic perturbations with scRNA-seq readouts

  • Cell-specific manipulation of UBA52 in complex tissues using targeted delivery systems

These emerging techniques will provide unprecedented insights into UBA52's cell-type specific functions, potentially revealing new therapeutic opportunities in diseases where UBA52 dysregulation contributes to pathology.

How might UBA52 research contribute to therapeutic developments for neurodegenerative diseases?

UBA52 research shows significant promise for therapeutic developments in neurodegenerative diseases, particularly Parkinson's disease, through several mechanistic pathways:

• Neuroprotective pathway modulation:

  • Evidence suggests decreased UBA52 abundance in Parkinson's disease models correlates with downregulation of tyrosine hydroxylase and neuronal death

  • Therapeutic angle: Stabilizing or increasing UBA52 levels could potentially preserve dopaminergic neurons

  • Approach: Screen for small molecules that enhance UBA52 expression or prevent its degradation in neuronal models

• Protein aggregation intervention:

  • UBA52 has demonstrated protein-protein interaction with α-synuclein and co-localization in mitochondria

  • Therapeutic angle: Modulating these interactions could potentially reduce toxic α-synuclein aggregation

  • Approach: Structure-based drug design targeting the UBA52-α-synuclein interface

• Protein quality control enhancement:

  • UBA52 plays a role in CHIP-mediated HSP90 ubiquitylation, with the lysine-63 residue being critical for this process

  • Therapeutic angle: Enhancing this pathway could improve clearance of misfolded proteins

  • Approach: Develop peptide mimetics that enhance K63-specific ubiquitination by UBA52

• Proteasome activity regulation:

  • Myc-UBA52 expressed neurons show increased proteasome activity in disease conditions

  • Therapeutic angle: Boosting UBA52-mediated enhancement of proteasome function

  • Approach: High-throughput screening for compounds that selectively enhance UBA52's effect on proteasome activity

• Combined biomarker and therapeutic targeting:

  • Develop dual-purpose approaches that both monitor disease progression and deliver therapeutic interventions

  • Example: Antibody-drug conjugates targeting UBA52-related pathologies while also providing imaging capabilities

Research approaches should include validation in multiple models, ranging from patient-derived iPSC neurons to transgenic animal models like the A53T transgenic mice , to establish clinical relevance and translatability of findings.

What are the most promising approaches for exploring UBA52's role in cancer biology?

UBA52's emerging role in cancer biology, particularly in hepatocellular carcinoma , opens several promising research avenues:

• Comprehensive cancer type profiling:

  • Analyze UBA52 expression across cancer types using TCGA and GEPIA databases

  • Correlate expression with patient outcomes, tumor characteristics, and molecular subtypes

  • Identify cancer types beyond HCC where UBA52 may serve as a prognostic marker or therapeutic target

• Mechanistic dissection of cancer-promoting pathways:

  • Further investigate UBA52's regulation of autophagy via EMC6 in HCC

  • Explore potential roles in other cancer hallmarks:

    • Metabolic reprogramming

    • Immune evasion

    • Metastatic cascade

  • Employ CRISPR/Cas9 screens to identify synthetic lethal interactions with UBA52 in cancer cells

• Translational model development:

  • Patient-derived xenografts (PDXs) with modulated UBA52 expression

  • Genetically engineered mouse models (GEMMs) with tissue-specific UBA52 alterations

  • Organoid models to study UBA52's role in a 3D tissue context

  • Testing combinations of UBA52 modulation with standard-of-care treatments

• Therapeutic targeting strategies:

  • Direct targeting approaches:

    • RNA interference therapeutics (siRNA/shRNA) delivered via nanoparticles

    • Small molecule modulators of UBA52 expression or function

    • Proteolysis-targeting chimeras (PROTACs) to induce UBA52 degradation

  • Indirect targeting approaches:

    • Targeting UBA52-dependent pathways like EMC6-mediated autophagy

    • Exploiting cancer-specific vulnerabilities created by altered UBA52 expression

• Biomarker development pipeline:

  • Tissue-based assays for UBA52 expression in tumor biopsies

  • Liquid biopsy approaches to detect circulating UBA52 or related markers

  • Development of companion diagnostics for potential UBA52-targeted therapies

This multifaceted approach would advance our understanding of UBA52's role in cancer biology while simultaneously developing potential therapeutic strategies and biomarkers for clinical application.